Catalog No.: PC-42840Not For Human Use, Lab Use Only.
Serdemetan (JNJ 26854165) is an anticancer agent that inhibits the function of the E3 ligase HDM2, dose-dependently inhibits proliferation in both wild-type and mutant p53 cell lines with IC50 of 0.25-3 uM.
Serdemetan (JNJ 26854165) is an anticancer agent that inhibits the function of the E3 ligase HDM2, dose-dependently inhibits proliferation in both wild-type and mutant p53 cell lines with IC50 of 0.25-3 uM.
Serdemetan (JNJ 26854165) induces p53-mediated apoptosis in acute leukemia cells with wild-type p53, accelerates the proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53, induces S-phase delay and upregulates E2F1 expression in p53 mutant cells.
Serdemetan (JNJ 26854165) demonstrates radiosensitizing activity in vitro and in tumor xenografts.
